ForesightIQ vs. Evaluate

Evaluate forecasts pharma drug sales from analyst consensus. ForesightIQ captures behavioral intelligence from digital exhaust — across any industry, in real time.

Overview

Compare ForesightIQ's real-time behavioral intelligence with Evaluate's pharma consensus forecasting.

Evaluate

Evaluate (part of Norstella) provides pharma and medtech consensus forecasts and pipeline analytics. Enterprise pricing typically runs $20K-$50K+/year.

Evaluate Evaluate (part of Norstella) provides pharma and medtech consensus forecasts and pipeline analytics. Enterprise pricing typically runs $20K-$50K+/year.

Different intelligence models.

  • Leading vs. Lagging: ForesightIQ captures real-time behavioral signals. Evaluate aggregates analyst consensus that's already priced in.
  • Cross-Industry vs. Pharma: ForesightIQ works across industries. Evaluate covers pharma/medtech only.

Feature Comparison

See how ForesightIQ stacks up against Evaluate across key capabilities.

FeatureForesightIQEvaluate
Cross-Industry Coverage
Real-Time Behavioral Signals
Digital Exhaust Intelligence
Consensus Forecasts
Pipeline Analytics

Key Differences

Real-time behavioral vs. periodic consensus

ForesightIQ captures what companies do as it happens. Evaluate reflects what analysts think after the fact. One leads, the other lags.

Side by Side

ForesightIQ vs Evaluate: Side by Side

ForesightIQ Approach

Focus Pharmaceutical and medtech consensus forecasts, pipeline analytics, and commercial assessments.

Value Proposition Aggregated analyst forecasts projecting drug sales, pipeline values, and company revenues.

Key Differentiator Consensus forecast models combining multiple sell-side analyst estimates for pharma/medtech.

Ideal For Pharma corporate strategy, sell-side/buy-side healthcare analysts, and investor relations teams.

Information Delivery Database with forecast models, pipeline analytics, and exportable reports.

Strategic Value Strong for pharma financial forecasting. No behavioral signals, no cross-industry coverage.

Evaluate Approach

Focus Pharmaceutical and medtech consensus forecasts, pipeline analytics, and commercial assessments.

Value Proposition Aggregated analyst forecasts projecting drug sales, pipeline values, and company revenues.

Key Differentiator Consensus forecast models combining multiple sell-side analyst estimates for pharma/medtech.

Ideal For Pharma corporate strategy, sell-side/buy-side healthcare analysts, and investor relations teams.

Information Delivery Database with forecast models, pipeline analytics, and exportable reports.

Strategic Value Strong for pharma financial forecasting. No behavioral signals, no cross-industry coverage.

Why ForesightIQ

Why Choose ForesightIQ Over Evaluate?

Leading Indicators vs. Consensus Estimates

Analyst consensus is a lagging indicator — it reflects what the market already knows. ForesightIQ captures leading indicators from digital exhaust: hiring surges, product changes, ad strategy shifts that precede consensus updates.

Benefits

Evaluate aggregates analyst consensus forecasts for pharma drug sales and pipelines. ForesightIQ captures the behavioral intelligence that consensus models miss — the digital exhaust signals that reveal what companies are actually doing before analysts update their models.

Ready to see the difference?

Get a personalized demo and see how ForesightIQ surfaces intelligence Evaluate can't.

Book a Demo